Sponsor
Thomas Bryant Cotton
Senator · R-AR
The bill uses substantial tax incentives and elective payment options to drive onshore production of generics and biosimilars and improve drug supply reliability, but it reduces federal revenue, creates compliance burdens, and includes exclusions, deadlines, and nonrefundable features that may disadvantage some smaller firms and complicate administration.
Manufacturers and investors in U.S. generic and biosimilar production receive substantial tax incentives (a 25% credit on qualifying capital investment plus a 30–35% value-added credit and potential bonuses), lowering project and production costs and making domestic manufacturing more financially attractive.
Patients (especially those with chronic conditions) and health systems benefit from expanded domestic production, which can improve drug supply reliability and reduce shortages of generics and biosimilars.
Eligible producers can elect payment or transfer the credit (or receive an elective payment), improving liquidity and lowering financing barriers for new facilities and projects.
Entities owned or controlled by designated 'foreign entities of concern' are barred from the credits and the program requires screening, which complicates ownership structures and may deter foreign investment (including permissible investors wary of compliance risk).
The tax incentives reduce federal revenue and elective payouts/expensing can shift near-term budget costs, potentially increasing deficits or crowding out other spending unless offsets are provided.
Credits that are nonrefundable, have phase-outs/sunsets, and include construction-start/in-service deadlines create cash-flow and timing pressure that may prevent firms without current tax liability or smaller developers from realizing full benefits.
Based on analysis of 3 sections of legislative text.
Creates two tax incentives to boost domestic production of generic drugs and biosimilars: a production-based nonrefundable tax credit that pays a percentage of value added for eligible components made and sold in the U.S., and a 25% investment tax credit for qualified facilities that produce these products. The production credit has higher rates for final drug production, a domestic-content bonus, an exclusion for ‘‘foreign entities of concern,’’ and a scheduled phaseout after 2030; the investment credit applies to property whose construction begins by the end of 2028 and to property placed in service after 2026.
Senator · R-AR
Creates a production tax credit for U.S.-made generics/biosimilars and a 25% investment tax credit for qualified domestic production facilities with timing and phaseout rules.
Official title: Amend the Internal Revenue Code of 1986 to establish the generic drugs and biosimilars production credit, and for other purposes.
Introduced May 22, 2025 by Thomas Bryant Cotton · Last progress May 22, 2025